MAGEA3 (MAGE Family Member A3)

We developed a novel 4-ARGs prognostic model and identified NLRX1 as a potential autophagy-dependent biomarker. These findings underscore its utility as a valuable tool for prognosis, risk stratification, and therapy guidance in ESCC.

These findings suggest that active smoking creates an immunosuppressive TME, potentially facilitating rapid tumor growth and aggressive progression. Smoking cessation may reverse these changes, highlighting the clinical significance of smoking behavior in disease outcomes.

Serum MAGEA3-IgG levels are significantly elevated in LUAD patients, and this autoantibody is anticipated to serve as a critical biomarker for early diagnosis, treatment monitoring, and prognostic evaluation in LUAD.

Further analysis confirmed that BCL11B and PAEP expression levels were significantly associated with immune cell infiltration and immune regulatory activity. MAGEA3/6 expression defines immune subtypes in GC and highlights potential targets for immunotherapy.

Our findings underscore the value of the ARDitox in silico method for the early and reliable identification of off-target epitopes for further preclinical evaluation. This platform strongly supports the development of safer TCR-mediated immunotherapies.

We present a proof-of-concept CTA-based genetic diagnostic tool capable of discriminating nodal involvement in oral tongue cancer. This approach may reduce unnecessary neck dissections, minimizing surgical morbidity.

IRF9, which regulates type I interferon (IFN-I) signaling, was upregulated in MPE. Therefore, targeted delivery of IFN-I to the pleural cavity may offer a feasible approach for the treatment of MPE.

We recommend further investigation and experimental validation in the case of M6PR, IDO1, NRP1, and MAGEA3 expressions based on their strong predictive power in GC ITR. Well-designed studies with larger sample sizes and nonlinear ML models might help improve biomarker selections.

P1/2, N=15, Suspended, Cancer Research UK | Trial completion date: Oct 2026 --> Mar 2029

Finally, the hub gene COL5A1 was obviously correlated with B cells memory, dendritic cells activated, macrophages M0, macrophages M2, plasma cells, T cells follicular helper in GC. This study reveals a novel tumor differentiation grade-related genes signature, and COL5A1 represents a promising biomarker in GC.

Clinically, our findings demonstrated that high baseline levels of MAGEA3 in CRC patients were strongly associated with worse progression-free survival (PFS) following bevacizumab treatment. Collectively, these findings position MAGEA3 as a promising predictive biomarker for bevacizumab resistance in CRC, offering a potential solution to the longstanding challenge of treatment stratification.

P1/2, N=15, Suspended, Cancer Research UK | N=103 --> 15 | Trial completion date: Dec 2027 --> Oct 2026 | Trial primary completion date: Dec 2027 --> Sep 2024